Sacubitril/valsartan after bypass to treat moderate ischemic mitral regurgitation
Official title: Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
Run by China National Center for Cardiovascular Diseases · NCT06917664 · Data updated 2026-11-12
This trial will test whether the drug sacubitril/valsartan can reduce moderate ischemic mitral regurgitation in people with coronary artery disease who have had isolated coronary artery bypass grafting (CABG).
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | China National Center for Cardiovascular Diseases Government |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | June 5, 2025 |
| Main results expected | December 2026 |
| Study ends | June 2027 |
| Registry record updated | August 27, 2025 |
| Trial ID | NCT06917664 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with coronary artery disease who underwent isolated CABG and had moderate ischemic mitral regurgitation confirmed on two preoperative echocardiograms and who meet blood pressure and lab safety limits.
✕Probably not a fit
Patients with symptomatic low blood pressure, estimated GFR under 30 mL/min/1.73 m2, serum potassium over 5 mmol/L, a history of angioedema with ACE inhibitors/ARBs, or those receiving concurrent mitral valve intervention are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, controlled trial testing sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) given after isolated CABG in patients with moderate ischemic mitral regurgitation. Patients are enrolled if they had moderate IMR confirmed on two consecutive preoperative transthoracic echocardiograms and meet safety labs and blood pressure criteria. The main outcome is change in mitral regurgitation severity and related cardiac remodeling measured by echocardiography over follow-up. Key exclusions include symptomatic hypotension, severe renal dysfunction, high serum potassium, history of angioedema with RAAS blockers, or concurrent mitral valve interventions.
Why it matters
Potential benefit: If successful, the treatment could reduce mitral regurgitation severity and improve heart function and symptoms, possibly avoiding additional mitral procedures.
How similar studies have gone: ARNI therapy (sacubitril/valsartan) has shown clear benefits in heart failure and some promise for reverse remodeling and reducing functional mitral regurgitation, but its specific use to treat ischemic MR after CABG is relatively novel and less well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Fully informed and voluntarily signed informed consent; 2. Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards ) Exclusion Criteria: 1.Symptomatic hypotension and/or a SBP \< 100 mmHg at screening; 2.Estimated GFR \< 30 mL/min/1.73m2; 3.Serum potassium \> 5 mmol/L at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.
Where it's running
-
China National Center for Cardiovascular Diseases
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Lianxin Chen, M.D.
- Email: chenlianx1@163.com
- Phone: 010-88322265
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.